MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
59.36
+0.16
+0.26%
Opening 14:49 04/09 EDT
OPEN
58.70
PREV CLOSE
59.20
HIGH
59.69
LOW
58.56
VOLUME
3.18M
TURNOVER
--
52 WEEK HIGH
62.24
52 WEEK LOW
41.46
MARKET CAP
121.19B
P/E (TTM)
17.16
1D
5D
1M
3M
1Y
5Y
1D
B of A Securities Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $67
Benzinga · 2h ago
Bristol Myers price target lowered to $67 from $68 at BofA
TipRanks · 5h ago
Oxford BioTherapeutics Partners Bristol Myers Squibb On T-Cell Engager Therapies For Solid Tumors
NASDAQ · 6h ago
Oxford BioTherapeutics Teams Up With Bristol Myers Squibb To Develop New Cancer Treatments
Benzinga · 7h ago
Bristol-Myers Squibb Earnings Preview: What to Expect
Barchart · 11h ago
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst
Benzinga · 1d ago
CEO of top pharma lobby PhRMA to resign: Endpoints News
Seeking Alpha · 1d ago
Bristol-Myers Squibb Price Target Maintained With a $72.00/Share by Guggenheim
Dow Jones · 1d ago
More
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.